Bob Smith Joins the ATiO Advisory Board

We are thrilled to announce that Bob Smith has joined the Advisory Board of the ATiO Foundation, bringing with him a wealth of experience in gene therapy, rare diseases, and biopharmaceutical leadership. His expertise will play a crucial role in advancing ATiO’s mission to drive innovation in advanced therapies for musculoskeletal conditions.

A Career Dedicated to Innovation

Bob Smith has over 35 years of experience in the biopharmaceutical industry, with a career that spans corporate leadership, business development, and scientific innovation. He most recently served as Senior Vice President of the Global Gene Therapy Business at Pfizer Inc., where he led the company’s efforts in gene therapy and rare diseases, overseeing strategic development, commercialization, and operational implementation. Under his leadership, Pfizer made significant advancements in its gene therapy pipeline, further establishing its position as a leader in the field.

Prior to his tenure at Pfizer, Smith held several senior leadership positions at Wyeth Pharmaceuticals, where he was responsible for global mergers and acquisitions. Following Pfizer’s acquisition of Wyeth in 2009, he transitioned into key roles within Pfizer’s business development division, overseeing global strategy across multiple therapeutic areas, including rare diseases, consumer healthcare, and animal health.

A Strong Advocate for Regenerative Medicine

Beyond his corporate work, Smith has been a key figure in the regenerative medicine community. He has served for over seven years on the Board of Directors of the Alliance for Regenerative Medicine (ARM), where he is currently the Chair. ARM is a leading international advocacy organization dedicated to the advancement of engineered cell therapies, gene therapies, and regenerative medicine innovations. His role at ARM has involved shaping policy, advocating for investment, and driving forward research collaborations.

Additionally, Smith has played a critical role in supporting emerging biotech companies by serving on advisory boards, offering strategic guidance to start-ups, and fostering partnerships between academia and industry to accelerate clinical applications of new therapies.

A Valuable Addition to the ATiO Foundation

At the ATiO Foundation, Bob Smith’s extensive expertise will be instrumental in guiding the foundation’s initiatives in advanced orthopaedic therapies. His deep knowledge of gene therapy, biopharmaceutical development, and regenerative medicine will contribute significantly to ATiO’s mission of bridging the gap between research, clinical application, and industry adoption.

His appointment to the Advisory Board comes at a pivotal time as ATiO continues to expand its global collaborations, including partnerships with organizations like the Japanese Society for Regenerative Medicine (JSRM) and the International Cartilage Regeneration and Joint Preservation Society (ICRS). Smith’s insights and leadership will help ATiO drive forward new initiatives, support emerging companies, and create meaningful connections between industry leaders, researchers, and investors.

We are honored to welcome Bob Smith to the ATiO Advisory Board and look forward to the impact his leadership will bring to the future of regenerative and orthopaedic therapies.